Congress Coverage: EHA 2021 – Focus on Leukemia and MDS
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Charles Craddock, CBE, FRCP, FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK
Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA
Nicola Gökbuget, MD
University Hospital Frankfurt, Frankfurt am Main, Germany
Gert Ossenkoppele, MD, PhD
VU University Medical Center Amsterdam , Amsterdam, the Netherlands
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX, USA
Jae Park, MD
Memorial Sloan Kettering, New York, NY, USA
Philippe Rousselot, MD, PhD
Versailles Hospital Center, Le Chesnay-Rocquencourt, France
Valeria Santini, MD
University of Florence, Firenze, Italy
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Updates on MDS
- Newly diagnosed AML patients
- IDH1/2 and FLT3 mutations in newly diagnosed AML patients
- FLT3 mutations in relapsed/refractory AML patients
- IDH1/2 mutations in relapsed/refractory AML patients
- Updates in ALL
